Document 3006
 DOCN  M94A3006
 TI    Hodgkin's disease and HIV infection (HD-HIV) in 114 patients (pts).
       GICAT.
 DT    9412
 AU    Errante D; Serraino D; Franceschi S; Nasti G; Bernardi D; Boiocchi M;
       Carbone A; Tirelli U; Rossi G; Ridolfo A; Division of Medical Oncology
       and AIDS, Centro di Riferimento; Oncologico, Aviano, Italy.
 SO    Int Conf AIDS. 1994 Aug 7-12;10(1):175 (abstract no. PB0126). Unique
       Identifier : AIDSLINE ICA10/94369569
 AB    OBJECTIVE: To evaluate the epidemiological, virological, pathological
       and clinical features of HD-HIV in 144 pts of the GICAT. METHODS: Since
       November 1986, 114 cases (103 m, 11 f) of HD-HIV have been collected by
       the GICAT. A comparison with 125 Italian HD pts not infected with HIV,
       observed in the same period of time at our Institution and with a
       comparable median age was made. RESULTS: The median age was 29 years
       (19-57), 80% were IVDU in accordance to the overall epidemiology of HIV
       infection in Italy. At the diagnosis of HD, 17% of pts had AIDS, 22%
       ARC, 29% PGL and 34% were asymptomatic; median CD4+ cell count was
       275/mm3 (9-1100). Lymphocyte predominance (LP) was observed in 4%,
       nodular sclerosis (NS) in 30%, mixed cellularity (MC) in 44% and
       lymphocyte depletion (LD) in 21% of pts. A 4-fold higher frequency of
       the MC and an approximately 12-fold higher frequency of the LD subtypes
       were detected among pts with HD-HIV in comparison with the Italian HD
       pts not infected with HIV. EBV was detected in 14/18 (78%) HD samples
       from the former group, but only in 27/104 (25%) HD samples from the
       latter group (p < 0.001) indicating that EBV may be more
       pathogenetically involved in HD-HIV, as previously reported for
       HIV-associated NHLs. Thirty-one/108 (28%) and 56/108 (51%) pts were
       stage III and IV respectively; 78% of pts had B symptoms. These figures
       were significantly different from those observed in pts with HD of the
       general population. Twenty six pts were treated prospectively with EBV
       +/- P (Epirubicin, Bleomycin, Vinblastine +/- Prednisone) + AZT +/-
       G-CSF and obtained 58% CR and 27% PR. The median survival of all pts was
       15.3 months. Pts with CD4+ lymphocytes < or = 250/mm3 at onset of HD had
       a median survival of 11.5 months, while those with CD4+ > 250/mm3 a
       median of 38 months (p = 0.002). The median survival of pts without and
       with AIDS at onset of HD was 27 months and 9 months respectively (p <
       0.001) and for pts achieving or not CR was 58 months and 11 months
       respectively (p < 0.001). The median survival of 26 pts treated with EBV
       +/- P + AZT +/- G-CFS was not different (13 months) from that of pts
       treated with standard CT (17 months) but a statistically significant
       lower rate of opportunistic infections (OI) occurred in the first group
       (32% vs 74%, p = 0.003) during or after treatment. DISCUSSION AND
       CONCLUSIONS. In comparison to HIV-negative HD there is evidence of a
       significant increase of: 1) MC and LD subtypes, 2) EBV expression in
       tumor tissue. Moreover, there is evidence of feasibility of
       antiretroviral therapy and CT with a significant reduction of OI.
 DE    Adult  Causality  Comorbidity  Cross-Sectional Studies  Female
       Hodgkin's Disease/*COMPLICATIONS/EPIDEMIOLOGY/PATHOLOGY  Human  HIV
       Infections/*COMPLICATIONS/EPIDEMIOLOGY/PATHOLOGY  Incidence
       Italy/EPIDEMIOLOGY  Lymph Nodes/PATHOLOGY  Male  Middle Age  Neoplasm
       Staging  Support, Non-U.S. Gov't  MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).